Old Web
English
Sign In
Acemap
>
Paper
>
PL02.03 Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial
PL02.03 Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial
2021
Luis Paz-Ares
Tudor-Eliade Ciuleanu
Atilio Navarro
Andrea Fülöp
S. Cousin
Laura Bonanno
Egbert F. Smit
Alberto Chiappori
María Eugenia Olmedo
I. Horvath
Christian Grohé
J A Lopez-Vilariño
Rafael Núñez
A. Nieto
M. Cullell
N. Vasco
Carmen Kahatt
Ali Zeaiter
Enric Carcereny
J. Roubec
Kostas N. Syrigos
G. Lo
I. Barneto
Keywords:
Lurbinectedin
Doxorubicin
Oncology
Medicine
Internal medicine
Topotecan
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI
[]